Professor Francis Ka-Leung Chan is a globally renowned gastroenterologist and Professor of Medicine at The Chinese University of Hong Kong (CUHK). With extensive expertise in education, research, and clinical practice, he is also a distinguished entrepreneur. He revolutionized the management of NSAID- and aspirin-induced gastrointestinal bleeding worldwide and currently focuses his research on the clinical applications of gut microbiota. Author of over 860 peer-reviewed articles with an h-index of 108, he has earned prestigious honors, including the Honorary Doctorate from the Osaka Metropolitan University, Guanghua Engineering Science and Technology Prize from the Chinese Academy of Engineering, elected as a Foreign Member of the Academia Europaea, and the International Leadership Award from the American College of Gastroenterology.
In 2019, he co-founded the Microbiota I-Center (MagIC), Asia’s pioneering hub for microbiota innovation, and established two biotechnology spin-offs – GenieBiome Ltd and MicroSigX Ltd – dedicated to translating microbiome research into clinical solutions, with the mission of bringing health and hope to future generations and helping transform Hong Kong into an international innovation and technology hub in Asia. As an inventor, he has secured many patents related to microbiome innovation, including the world’s first fecal “bacterial gene markers” test for colorectal cancer and an early-detection tool for autism spectrum disorder (ASD)
